Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3021% below fair value
$9.96−2.16 (-17.82%)
Close on Nov 13, 2026Market cap $1.69BP/E –Yield –
Vir Biotechnology total assets
Total assets on the balance sheet at the end of each period.
Vir Biotechnology's total assets was $1.11B at Sep 30, 2026. For fiscal 2025 it was $1.00B, down 28.3% from the year before. The highest annual figure on record is $2.80B in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.00B | -28.3% |
| FY2024 | Dec 31, 2024 | $1.40B | -27.1% |
| FY2023 | Dec 31, 2023 | $1.92B | -31.5% |
| FY2022 | Dec 31, 2022 | $2.80B | +43.4% |
| FY2021 | Dec 31, 2021 | $1.95B | +112.7% |
| FY2020 | Dec 31, 2020 | $918.76M | +79.4% |
| FY2019 | Dec 31, 2019 | $512.07M | +167.3% |
| FY2018 | Dec 31, 2018 | $191.60M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.11B | +9.1% |
| Q2 FY2026 | Jun 30, 2026 | $1.21B | +1.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.03B | -21.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.00B | -28.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.02B | -32.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.19B | -28.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.31B | -27.1% |
| Q4 FY2024 | Dec 31, 2024 | $1.40B | -27.1% |
| Q3 FY2024 | Sep 30, 2024 | $1.50B | -26.7% |
| Q2 FY2024 | Jun 30, 2024 | $1.67B | -25.6% |
| Q1 FY2024 | Mar 31, 2024 | $1.79B | -32.7% |
| Q4 FY2023 | Dec 31, 2023 | $1.92B | -31.5% |
| Q3 FY2023 | Sep 30, 2023 | $2.04B | -24.1% |
| Q2 FY2023 | Jun 30, 2023 | $2.24B | -14.3% |
| Q1 FY2023 | Mar 31, 2023 | $2.67B | -7.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.80B | +43.4% |
| Q3 FY2022 | Sep 30, 2022 | $2.70B | +122.8% |
| Q2 FY2022 | Jun 30, 2022 | $2.62B | +147.6% |
| Q1 FY2022 | Mar 31, 2022 | $2.89B | +154.2% |
| Q4 FY2021 | Dec 31, 2021 | $1.95B | +112.7% |
| Q3 FY2021 | Sep 30, 2021 | $1.21B | +28.3% |
| Q2 FY2021 | Jun 30, 2021 | $1.06B | +57.3% |
| Q1 FY2021 | Mar 31, 2021 | $1.14B | +138.0% |
| Q4 FY2020 | Dec 31, 2020 | $918.76M | +79.4% |
| Q3 FY2020 | Sep 30, 2020 | $943.26M | +123.2% |
| Q2 FY2020 | Jun 30, 2020 | $672.24M | +250.9% |
| Q1 FY2020 | Mar 31, 2020 | $477.11M | – |
| Q4 FY2019 | Dec 31, 2019 | $512.07M | – |
| Q3 FY2019 | Sep 30, 2019 | $422.64M | – |
| Q4 FY2018 | Dec 31, 2018 | $191.60M | – |
See a number that looks wrong?